2018. Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance. SKIN The Journal of Cutaneous Medicine. 2, (Dec. 2018), S57. DOI:https://doi.org/10.25251/skin.2.supp.57.